Piramal Enterprises (formely known as Piramal Healthcare) is a pharmaceutical healthcare company based in Mumbai, India. It entered into pharmaceutical sector in 1988. Piramal’s pharmaceutical businesses comprises pharma solutions, critical care, consumer products and lab-diagnostics, which contributes to over 90 percent of the company’s revenues. The health care vertical of PEL is further divided into the key business divisions.
The UN Conference on Trade and Development’s World Investment Report 2011 ranked Piramal Enterprises' CMO (contract manufacturing) business vertical as number five in the top 10 pharmaceutical contract manufacturers worldwide; and was awarded the number one position amongst all Indian CMOs.
It recently bought regenerative medical device BST-CarGel from BioSyntech, Canada. They also set up a new company called Piramal Imaging, when they acquired the molecular imaging arm from Bayer pharma in Berlin, Germany.
Piramal Enterprises announced its Q4 and annual results for FY 2012 on 3 May 2012. Total operating income for the quarter was 688.1 crores. Income from investments for the quarter was 39.1 crores and operating profit (OPBITDA) was Rs 150.0 crores.
Read more about Piramal Healthcare: Pharma Business, Piramal Critical Care, Consumer Products and Over The Counter Division (OTC), Innovative Discovery & Commercialization, Other Sectors
Other articles related to "piramal healthcare, piramal, healthcare":
... Piramal Realty is Mr ... Ajay Piramal’s fully owned real estate venture ... Indiareit is Piramal Group’s real estate equity funding arm ...
... The OTC division of Piramal Enterprises Ltd, is one of the key businesses that the company retained after divesting its flagship formulations and diagnostics services units ... Piramal Healthcare is one of the fastest growing players in the Rs.11, 000 crore by sales domestic consumer healthcare market, which deals with non-prescription products ... Piramal Enterprises entered the OTC market with the acquisition of Saridon from Roche and Lacto Calamine from Duphar in the early 1990s ...